Hikma Pharmaceuticals (CHIX:HIKL) Additional Paid-In Capital : £223 Mil(As of Dec. 2023)

View and export this data going back to 2009. Start your Free Trial

What is Hikma Pharmaceuticals Additional Paid-In Capital?

Hikma Pharmaceuticals's quarterly additional paid-in capital declined from Dec. 2022 (£232 Mil) to Jun. 2023 (£225 Mil) but then stayed the same from Jun. 2023 (£225 Mil) to Dec. 2023 (£223 Mil).

Hikma Pharmaceuticals's annual additional paid-in capital increased from Dec. 2021 (£212 Mil) to Dec. 2022 (£232 Mil) but then declined from Dec. 2022 (£232 Mil) to Dec. 2023 (£223 Mil).

Hikma Pharmaceuticals Additional Paid-In Capital Historical Data

The historical data trend for Hikma Pharmaceuticals's Additional Paid-In Capital can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Hikma Pharmaceuticals Additional Paid-In Capital Chart

Hikma Pharmaceuticals Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Additional Paid-In Capital

Get a 7-Day Free Trial

215.17

209.81

212.06

231.52

222.78

Hikma Pharmaceuticals Semi-Annual Data
	Jun14	Dec14	Jun15	Dec15	Jun16	Dec16	Jun17	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23
Additional Paid-In Capital	Get a 7-Day Free Trial															212.06	228.98	231.52	224.93	222.78

Hikma Pharmaceuticals Additional Paid-In Capital Calculation

Capital that a company raises in a financing round in excess of the capital's par value. The account represents the excess paid by an investor over the par-value price of a stock issue. Additional paid-in-capital can arise from issuing either preferred or common stock.

Additional Paid-In Capital is calculated as

Additional Paid-In Capital

(Issue Price

Par Value)

Shares Outstanding (Diluted Average)

Hikma Pharmaceuticals Additional Paid-In Capital Related Terms

Thank you for viewing the detailed overview of Hikma Pharmaceuticals's Additional Paid-In Capital provided by GuruFocus.com. Please click on the following links to see related term pages.

Hikma Pharmaceuticals Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Hikma Pharmaceuticals PLC (CHIX:HIKl) » Definitions » Additional Paid-In Capital

Comparable Companies

Traded in Other Exchanges

HKMPY:USA HKMPF:USA HIK:UK H5P:Germany

Address

1 New Burlington Place, London, GBR, W1S 2HR

Website

https://www.hikma.com

Hikma Pharmaceuticals PLC is engaged in developing, manufacturing, and marketing a broad range of generic, branded and non-branded, in-licensed pharmaceutical products. The firm operates in three segments: injectables, generics, and branded. The majority of the revenue for the company is generated from its injectables segment under which it supplies hospitals across markets with generic injectable products, supported by its manufacturing facilities. Geographically, North America is the company's key revenue generating market followed by Middle East and North Africa, United Kingdom, Europe and the rest of the world.

Hikma Pharmaceuticals Headlines

No Headlines